Signal or noise? > StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA
Draft Guidance - Genetic Engineering and Biotechnology News >> Comment below! #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #healthcare #pharmaceutical #biotech
Draft Guidance - Genetic Engineering and Biotechnology News >> Comment below! #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #healthcare #pharmaceutical #biotech
StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA
Draft Guidance - Genetic Engineering and Biotechnology News
StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance Genetic Engineering and Biotechnology News
dlvr.it
November 1, 2026 at 10:23 PM
Signal or noise? > StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA
Draft Guidance - Genetic Engineering and Biotechnology News >> Comment below! #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #healthcare #pharmaceutical #biotech
Draft Guidance - Genetic Engineering and Biotechnology News >> Comment below! #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #healthcare #pharmaceutical #biotech
Stocks of gene editing therapy companies rose by double digits following data from the ESGCT Congress and new FDA draft guidance on personalized genome editing products.
#GeneEditing #FDA #Esgct
#GeneEditing #FDA #Esgct
Gene editing therapy company shares increased by double digits
Source: GEN (Genetic Eng News)
realfeedapp.com
November 2, 2026 at 7:20 AM
Stocks of gene editing therapy companies rose by double digits following data from the ESGCT Congress and new FDA draft guidance on personalized genome editing products.
#GeneEditing #FDA #Esgct
#GeneEditing #FDA #Esgct
Signal or noise? > ESGCT 2026: AAVs cross tissues and cells tracing toxicity
routes - BioWorld News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma
routes - BioWorld News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma
ESGCT 2026: AAVs cross tissues and cells tracing toxicity
routes - BioWorld News
ESGCT 2026: AAVs cross tissues and cells tracing toxicity routes BioWorld News
dlvr.it
October 30, 2026 at 4:27 PM
Signal or noise? > ESGCT 2026: AAVs cross tissues and cells tracing toxicity
routes - BioWorld News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma
routes - BioWorld News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma
Signal or noise? > ESGCT 2026: AAVs cross tissues and cells tracing toxicity
routes - BioWorld News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma
routes - BioWorld News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma
ESGCT 2026: AAVs cross tissues and cells tracing toxicity
routes - BioWorld News
ESGCT 2026: AAVs cross tissues and cells tracing toxicity routes BioWorld News
dlvr.it
October 30, 2026 at 4:27 PM
Signal or noise? > ESGCT 2026: AAVs cross tissues and cells tracing toxicity
routes - BioWorld News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma
routes - BioWorld News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TW6zCB #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
@ASGCTherapy @ESGCT
October 30, 2026 at 4:00 PM
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TW6zCB #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
@ASGCTherapy @ESGCT
→ What they did
Shares of gene editing therapy companies surged due to data presented at the ESGCT Congress and new FDA draft guidance on personalized genome editing.
Shares of gene editing therapy companies surged due to data presented at the ESGCT Congress and new FDA draft guidance on personalized genome editing.
November 2, 2026 at 7:20 AM
→ What they did
Shares of gene editing therapy companies surged due to data presented at the ESGCT Congress and new FDA draft guidance on personalized genome editing.
Shares of gene editing therapy companies surged due to data presented at the ESGCT Congress and new FDA draft guidance on personalized genome editing.
Gene editing therapy companies have seen a notable increase in share value following recent developments at the European Society of Gene and Cell Therapy’s Annual Co...
🔗 Source: https://www.genengnews.com/topics/genome-editing/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance/
🔗 Source: https://www.genengnews.com/topics/genome-editing/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance/
November 2, 2026 at 4:17 AM
Gene editing therapy companies have seen a notable increase in share value following recent developments at the European Society of Gene and Cell Therapy’s Annual Co...
🔗 Source: https://www.genengnews.com/topics/genome-editing/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance/
🔗 Source: https://www.genengnews.com/topics/genome-editing/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance/
David Liu highlights advancements in disease-agnostic gene editing, underscoring synergies between scientific approaches and regulatory progress.
🔗 Source: https://www.genengnews.com/topics/genome-editing/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct/
🔗 Source: https://www.genengnews.com/topics/genome-editing/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct/
October 31, 2026 at 4:13 AM
David Liu highlights advancements in disease-agnostic gene editing, underscoring synergies between scientific approaches and regulatory progress.
🔗 Source: https://www.genengnews.com/topics/genome-editing/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct/
🔗 Source: https://www.genengnews.com/topics/genome-editing/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct/
Nobel laureate David Liu stated that the synergy between scientific approaches and regulatory advances allows expanding genome editing applications beyond rare genetic diseases.
#GeneEditing #Crispr #ClinicalTrial
#GeneEditing #Crispr #ClinicalTrial
David Liu will return to ESGCT in 2019
Source: GEN (Genetic Eng News)
realfeedapp.com
October 30, 2026 at 4:40 PM
Nobel laureate David Liu stated that the synergy between scientific approaches and regulatory advances allows expanding genome editing applications beyond rare genetic diseases.
#GeneEditing #Crispr #ClinicalTrial
#GeneEditing #Crispr #ClinicalTrial
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TW6zCB #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
@ASGCTherapy @ESGCT
October 30, 2026 at 4:00 PM
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TW6zCB #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
@ASGCTherapy @ESGCT
#NGNE Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
https://www.stocktitan.net/news/NGNE/neurogene-presents-new-data-at-esgct-congress-that-reinforce-key-w7ka7horxc7c.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NGNE/neurogene-presents-new-data-at-esgct-congress-that-reinforce-key-w7ka7horxc7c.html?utm_source=stocktitan-bluesky&utm_medium=social
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 27, 2026 at 11:30 AM
#NGNE Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
https://www.stocktitan.net/news/NGNE/neurogene-presents-new-data-at-esgct-congress-that-reinforce-key-w7ka7horxc7c.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NGNE/neurogene-presents-new-data-at-esgct-congress-that-reinforce-key-w7ka7horxc7c.html?utm_source=stocktitan-bluesky&utm_medium=social
BSGCT is at ESGCT 2026 in Hamburg from 27 to 30 October! Come say hi at the BSGCT stand and chat to Ouidad Khechaoui, Emily Bates and the team to learn more about Society membership, grants, awards, mentoring schemes and more.
#ESGCT2026 #BSGCT #CellAndGeneTherapy #Hamburg
#ESGCT2026 #BSGCT #CellAndGeneTherapy #Hamburg
October 28, 2026 at 4:24 PM
BSGCT is at ESGCT 2026 in Hamburg from 27 to 30 October! Come say hi at the BSGCT stand and chat to Ouidad Khechaoui, Emily Bates and the team to learn more about Society membership, grants, awards, mentoring schemes and more.
#ESGCT2026 #BSGCT #CellAndGeneTherapy #Hamburg
#ESGCT2026 #BSGCT #CellAndGeneTherapy #Hamburg
Are you in Hamburg for ESGCT? Come visit us! We’re at booth #C-03 ready to discuss how our gene editing solutions are helping researchers move discoveries forward with confidence.
Reminder: Visit our poster presentation on multiplexed empirical off-target nomination on October 29 from 2-4pm, #P0922
Reminder: Visit our poster presentation on multiplexed empirical off-target nomination on October 29 from 2-4pm, #P0922
October 28, 2026 at 7:30 AM
Heading to ESGCT this year?
Several MAGIC partners are ready and waiting to share their expertise!
We've created a poster featuring all MAGIC presentations across the four-day programme - take a look and come along to hear about the collaborative research taking place through the MAGIC consortium.
Several MAGIC partners are ready and waiting to share their expertise!
We've created a poster featuring all MAGIC presentations across the four-day programme - take a look and come along to hear about the collaborative research taking place through the MAGIC consortium.
October 27, 2026 at 9:32 AM
Heading to ESGCT this year?
Several MAGIC partners are ready and waiting to share their expertise!
We've created a poster featuring all MAGIC presentations across the four-day programme - take a look and come along to hear about the collaborative research taking place through the MAGIC consortium.
Several MAGIC partners are ready and waiting to share their expertise!
We've created a poster featuring all MAGIC presentations across the four-day programme - take a look and come along to hear about the collaborative research taking place through the MAGIC consortium.
𝐖𝐡𝐞𝐫𝐞 𝐭𝐨 𝐦𝐞𝐞𝐭 𝐍𝐨𝐯𝐨𝐠𝐞𝐧𝐞 𝐄𝐮𝐫𝐨𝐩𝐞 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤! Our teams will be attending several scientific events across Europe:
📍 𝐄𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 | 𝐇𝐚𝐦𝐛𝐮𝐫𝐠, 𝐆𝐞𝐫𝐦𝐚𝐧𝐲 | 𝟐𝟕 𝐎𝐜𝐭
📍 𝐄𝐍𝐋𝐈𝐆𝐇𝐓 𝐂𝐀𝐍𝐂𝐄𝐑 𝐃𝐀𝐘𝐒 | 𝐁𝐨𝐫𝐝𝐞𝐚𝐮𝐱, 𝐅𝐫𝐚𝐧𝐜𝐞 | 𝟐𝟖 𝐎𝐜𝐭
📍 𝐓𝐡𝐞 𝐌𝐞𝐭𝐍𝐞𝐭 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 | 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚, 𝐒𝐩𝐚𝐢𝐧 | 𝟐𝟗 𝐎𝐜𝐭
📍 𝐄𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 | 𝐇𝐚𝐦𝐛𝐮𝐫𝐠, 𝐆𝐞𝐫𝐦𝐚𝐧𝐲 | 𝟐𝟕 𝐎𝐜𝐭
📍 𝐄𝐍𝐋𝐈𝐆𝐇𝐓 𝐂𝐀𝐍𝐂𝐄𝐑 𝐃𝐀𝐘𝐒 | 𝐁𝐨𝐫𝐝𝐞𝐚𝐮𝐱, 𝐅𝐫𝐚𝐧𝐜𝐞 | 𝟐𝟖 𝐎𝐜𝐭
📍 𝐓𝐡𝐞 𝐌𝐞𝐭𝐍𝐞𝐭 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 | 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚, 𝐒𝐩𝐚𝐢𝐧 | 𝟐𝟗 𝐎𝐜𝐭
October 26, 2026 at 6:48 AM
𝐖𝐡𝐞𝐫𝐞 𝐭𝐨 𝐦𝐞𝐞𝐭 𝐍𝐨𝐯𝐨𝐠𝐞𝐧𝐞 𝐄𝐮𝐫𝐨𝐩𝐞 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤! Our teams will be attending several scientific events across Europe:
📍 𝐄𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 | 𝐇𝐚𝐦𝐛𝐮𝐫𝐠, 𝐆𝐞𝐫𝐦𝐚𝐧𝐲 | 𝟐𝟕 𝐎𝐜𝐭
📍 𝐄𝐍𝐋𝐈𝐆𝐇𝐓 𝐂𝐀𝐍𝐂𝐄𝐑 𝐃𝐀𝐘𝐒 | 𝐁𝐨𝐫𝐝𝐞𝐚𝐮𝐱, 𝐅𝐫𝐚𝐧𝐜𝐞 | 𝟐𝟖 𝐎𝐜𝐭
📍 𝐓𝐡𝐞 𝐌𝐞𝐭𝐍𝐞𝐭 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 | 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚, 𝐒𝐩𝐚𝐢𝐧 | 𝟐𝟗 𝐎𝐜𝐭
📍 𝐄𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 | 𝐇𝐚𝐦𝐛𝐮𝐫𝐠, 𝐆𝐞𝐫𝐦𝐚𝐧𝐲 | 𝟐𝟕 𝐎𝐜𝐭
📍 𝐄𝐍𝐋𝐈𝐆𝐇𝐓 𝐂𝐀𝐍𝐂𝐄𝐑 𝐃𝐀𝐘𝐒 | 𝐁𝐨𝐫𝐝𝐞𝐚𝐮𝐱, 𝐅𝐫𝐚𝐧𝐜𝐞 | 𝟐𝟖 𝐎𝐜𝐭
📍 𝐓𝐡𝐞 𝐌𝐞𝐭𝐍𝐞𝐭 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 | 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚, 𝐒𝐩𝐚𝐢𝐧 | 𝟐𝟗 𝐎𝐜𝐭
#BEAM Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Gen…
https://www.stocktitan.net/news/BEAM/beam-therapeutics-reports-initial-clinical-data-from-phase-1-2-trial-jayq3ufsog0c.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/BEAM/beam-therapeutics-reports-initial-clinical-data-from-phase-1-2-trial-jayq3ufsog0c.html?utm_source=stocktitan-bluesky&utm_medium=social
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 27, 2026 at 11:00 AM
#BEAM Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Gen…
https://www.stocktitan.net/news/BEAM/beam-therapeutics-reports-initial-clinical-data-from-phase-1-2-trial-jayq3ufsog0c.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/BEAM/beam-therapeutics-reports-initial-clinical-data-from-phase-1-2-trial-jayq3ufsog0c.html?utm_source=stocktitan-bluesky&utm_medium=social
#CLLS Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at…
https://www.stocktitan.net/news/CLLS/cellectis-presents-preclinical-data-highlighting-efficient-apoc3-z5rupwdtacuf.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLLS/cellectis-presents-preclinical-data-highlighting-efficient-apoc3-z5rupwdtacuf.html?utm_source=stocktitan-bluesky&utm_medium=social
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
Cellectis (CLLS) presented preclinical data for .HEAL-101, its gene-editing candidate for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress.The candidate targets APOC3, a driver of elevated triglycerides. In human liver cells, mean editing was approximately 90%, without DNA double-strand breaks at the target site. In mice with humanized livers and normal lipid levels, a single intravenous injection achieved approximately 65% mean human APOC3 editing, reaching up to 70%. In a separate mouse disease model, APOC3 fell 67% ± 12% (mean ± standard deviation); single-dose triglyceride reduction was highlighted at 76%. Editing was detected in the liver, with no significant activity in other tissues analyzed.Cellectis plans a Phase 1 investigator-initiated trial in China, with preliminary clinical data expected in the second half of 2027.
www.stocktitan.net
October 27, 2026 at 7:15 AM
#CLLS Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at…
https://www.stocktitan.net/news/CLLS/cellectis-presents-preclinical-data-highlighting-efficient-apoc3-z5rupwdtacuf.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLLS/cellectis-presents-preclinical-data-highlighting-efficient-apoc3-z5rupwdtacuf.html?utm_source=stocktitan-bluesky&utm_medium=social
J-7 avant #ESGCT2026 à Hambourg !
Les équipes de
@genethonfr.bsky.social r
présenteront leurs dernières avancées :
🔬 5 communications orales
📌 21 posters scientifiques
🤝 2 sessions coprésidées
👉 urlr.me/33RE7Z
@ESGCT
#ThérapieGénique #MaladiesRares #Recherche
Les équipes de
@genethonfr.bsky.social r
présenteront leurs dernières avancées :
🔬 5 communications orales
📌 21 posters scientifiques
🤝 2 sessions coprésidées
👉 urlr.me/33RE7Z
@ESGCT
#ThérapieGénique #MaladiesRares #Recherche
October 23, 2026 at 7:13 PM
J-7 avant #ESGCT2026 à Hambourg !
Les équipes de
@genethonfr.bsky.social r
présenteront leurs dernières avancées :
🔬 5 communications orales
📌 21 posters scientifiques
🤝 2 sessions coprésidées
👉 urlr.me/33RE7Z
@ESGCT
#ThérapieGénique #MaladiesRares #Recherche
Les équipes de
@genethonfr.bsky.social r
présenteront leurs dernières avancées :
🔬 5 communications orales
📌 21 posters scientifiques
🤝 2 sessions coprésidées
👉 urlr.me/33RE7Z
@ESGCT
#ThérapieGénique #MaladiesRares #Recherche
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TW0Yk4 #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
@ASGCTherapy @ESGCT
October 21, 2026 at 9:21 AM
🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TW0Yk4 #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT
@ASGCTherapy @ESGCT
#SLDB Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
https://www.stocktitan.net/news/SLDB/solid-biosciences-to-present-research-across-gene-therapy-xmkj4thawf66.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/SLDB/solid-biosciences-to-present-research-across-gene-therapy-xmkj4thawf66.html?utm_source=stocktitan-bluesky&utm_medium=social
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 20, 2026 at 12:00 PM
#SLDB Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
https://www.stocktitan.net/news/SLDB/solid-biosciences-to-present-research-across-gene-therapy-xmkj4thawf66.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/SLDB/solid-biosciences-to-present-research-across-gene-therapy-xmkj4thawf66.html?utm_source=stocktitan-bluesky&utm_medium=social
#NGNE Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual…
https://www.stocktitan.net/news/NGNE/neurogene-announces-upcoming-presentations-highlighting-key-yhfq4e9ou6wc.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NGNE/neurogene-announces-upcoming-presentations-highlighting-key-yhfq4e9ou6wc.html?utm_source=stocktitan-bluesky&utm_medium=social
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 20, 2026 at 11:30 AM
#NGNE Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual…
https://www.stocktitan.net/news/NGNE/neurogene-announces-upcoming-presentations-highlighting-key-yhfq4e9ou6wc.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NGNE/neurogene-announces-upcoming-presentations-highlighting-key-yhfq4e9ou6wc.html?utm_source=stocktitan-bluesky&utm_medium=social
@profsimonwad.bsky.social Hi Simon. Long time no speak. How’s things? Thought I’d get your insights on 2 cases of tumours demonstrated as being caused by AAV vectors. Should this be cause for concern more generally? Has this been raised/discussed at BSGCT/ESGCT?
October 19, 2026 at 8:02 AM
@profsimonwad.bsky.social Hi Simon. Long time no speak. How’s things? Thought I’d get your insights on 2 cases of tumours demonstrated as being caused by AAV vectors. Should this be cause for concern more generally? Has this been raised/discussed at BSGCT/ESGCT?
📅 CATALYST REMINDER | #$BEAM
October 27–28, 2026 — Phase 1/2 Data Discussion / Poster
BEAM-301 investor webcast Oct 27; initial Phase 1/2 GSD Ia data at ESGCT Oct 28.
🔗 Full details: www.merlintrader.com/beam-therape...
#BEAM #Biotech #GeneEditing
October 27–28, 2026 — Phase 1/2 Data Discussion / Poster
BEAM-301 investor webcast Oct 27; initial Phase 1/2 GSD Ia data at ESGCT Oct 28.
🔗 Full details: www.merlintrader.com/beam-therape...
#BEAM #Biotech #GeneEditing
Beam Therapeutics ($BEAM) Stock Hub: BEAM-302, Risto-cel
Beam Therapeutics (BEAM) stock hub: BEAM-302 ERS data, the risto-cel BLA guided as early as year-end 2026, $1.15bn of cash and a runway into mid-2029.
www.merlintrader.com
October 17, 2026 at 7:40 PM
📅 CATALYST REMINDER | #$BEAM
October 27–28, 2026 — Phase 1/2 Data Discussion / Poster
BEAM-301 investor webcast Oct 27; initial Phase 1/2 GSD Ia data at ESGCT Oct 28.
🔗 Full details: www.merlintrader.com/beam-therape...
#BEAM #Biotech #GeneEditing
October 27–28, 2026 — Phase 1/2 Data Discussion / Poster
BEAM-301 investor webcast Oct 27; initial Phase 1/2 GSD Ia data at ESGCT Oct 28.
🔗 Full details: www.merlintrader.com/beam-therape...
#BEAM #Biotech #GeneEditing